The Gazelle Hb Variant Test, one of the tests supported by the Gazelle diagnostic platform, can detect Sickle Cell Disease (SCD) and beta thalassemia. As an affordable, portable, point-of-care test, Gazelle’s results are equivalent to standard lab tests but do not require complex logistical support. Administration of the test requires minimal training and results are displayed in eight minutes, including hemoglobin percentages by type, and can be stored locally or transmitted to the Cloud for patient and disease tracking.